145 related articles for article (PubMed ID: 38859749)
1. Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
Ishii R; Ishizuchi K; Watanabe N; Fukazawa R; Trivedi M; Nakahara J; Takizawa T
Cephalalgia; 2024 Jun; 44(6):3331024241258695. PubMed ID: 38859749
[TBL] [Abstract][Full Text] [Related]
2. The Effect and Safety of 5-HT
Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
[TBL] [Abstract][Full Text] [Related]
3. Short-term efficacy and safety of lasmiditan, a novel 5-HT
Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
[TBL] [Abstract][Full Text] [Related]
5. Lasmiditan in patients with common migraine comorbidities: a
Clemow DB; Baygani SK; Hauck PM; Hultman CB
Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
[TBL] [Abstract][Full Text] [Related]
6. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
[TBL] [Abstract][Full Text] [Related]
7. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
[No Abstract] [Full Text] [Related]
8. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
Maiti R; Mishra A; Puliappadamb HM; Jena M; Srinivasan A
J Clin Pharmacol; 2021 Dec; 61(12):1534-1544. PubMed ID: 34472095
[TBL] [Abstract][Full Text] [Related]
10. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
11. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
13. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
[TBL] [Abstract][Full Text] [Related]
14. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
[TBL] [Abstract][Full Text] [Related]
15. Profiling lasmiditan as a treatment option for migraine.
Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
[No Abstract] [Full Text] [Related]
16. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
Zhou J; Luo G; Xu Y; Yang X; Pan X; Dong Z; Zhong S; Liu H; Ji F; Yu S
Adv Ther; 2022 Nov; 39(11):5229-5243. PubMed ID: 36114949
[TBL] [Abstract][Full Text] [Related]
17. Lasmiditan for the treatment of migraine.
Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.
Komori M; Ozeki A; Tanji Y; Kamiki E; Krege JH; Li LQ; Suzuki S; Shibata M; Takeshima T
J Headache Pain; 2024 Mar; 25(1):43. PubMed ID: 38528476
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
[TBL] [Abstract][Full Text] [Related]
20. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
